Endometriosis of the uterus
Conditions
Interventions
Treatment group with Dienogest 2mg orally, daily for 12 months with 40 women. Treatment group with Levorgestrel-releasing intrauterine system, which is an intrauterine device inserted that releases 20
C12.050.351.500.852.113
Sponsors
Universidade Estadual de Campinas - UNICAMP
Universidade Estadual de Campinas - UNICAMP
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women; age between 18 and 45 years old; diagnosis of adenomyosis, both by magnetic resonance imaging and transvaginal ultrasound; have agreed to participate in the study and signed the Free and informed consent form
Exclusion criteria
Exclusion criteria: Women with uterine fibroids, endometrial polyps and other structural causes of abnormal uterine bleeding; women with cardiovascular, hepatic, renal failure or any other contraindications for the use of progestogens or the intrauterine system; women not having initiated sexual activity; women who cannot read or have some cognitive deficit that prevents them from understanding the questionnaires and the informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A similar rate of amenorrhea and reduction in pain symptoms is expected in the three groups | — |
Secondary
| Measure | Time frame |
|---|---|
| A similar reduction in fatigue is expected in all three groups and a greater reduction in uterine volume is expected in the Levonorgestrel-releasing intrauterine system and Etonogestrel implant groups | — |
Countries
Brazil
Contacts
Public ContactDaniela Gomes
Universidade Estadual de Campinas - UNICAMP
Outcome results
None listed